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Abstract
Background: Mean platelet volume (MPV) and platelet distribution width (PDW) are indices that reflect platelet
activity. We investigated the association between these platelet indices and left ventricular hypertrophy and
cardiac function.
Methods: We analyzed the data of 1241 patients who were admitted to the Cardiology Department.
Results: Both MPV and PDW were selected as independent factors associated with left ventricular systolic and
diastolic dysfunction, and left ventricular hypertrophy. The highest tertile of MPV and PDW was associated with
left ventricular systolic dysfunction (left ventricular ejection fraction of <50 %) with an odds ratio of 1.53 and 2.03,
respectively, when the respective lowest tertile was used as reference. The highest PDW tertile was associated
with left ventricular hypertrophy with an odds ratio of 1.56 (95 % CI, 1.13–2.15) and with dysfunction with an
odds ratio of 3.34 (95 % CI, 1.54–7.25).
Conclusions: Indices of platelet activation (MPV and/or PDW) were independently associated positively with left
ventricular hypertrophy and left ventricular systolic and diastolic dysfunction. Whether these platelet indices
represent useful markers for identifying individuals at higher risk for thromboembolic disease and organ damage
among cardiac patients awaits further investigation.
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Background
Activation of platelets and their subsequent aggregation
play a key role in thrombus formation at the site of vas-
cular injury and atherothrombotic events [1, 2]. Assess-
ment of platelet activity and proper medical control are
therefore mandatory for high-risk patients [3]; however,
platelet aggregation after applying inducers, such as ad-
enosine diphosphate (ADP) or 5-hydroxytryptamine, and
collagen, is, in general, not measured in routine labora-
tory testing.
In comparison to smaller ones, larger platelets have
higher thrombotic potential [4] that may be partially
attributed to a higher thromboxane A2 level [5] and in-
creased expression of glycoprotein Ib and IIb/IIIa recep-
tors [6]. Mean platelet volume (MPV), which is the most
accurate measure of platelet size, is a simple, easy to
quantify, inexpensive, and widely available marker of
platelet activation [7]. MPV has received substantial at-
tention in the past few years for the purpose of risk pre-
diction and risk stratification of various disorders,
especially ischemic heart disease, in the cardiology field
[4, 8–11]. Platelet distribution width (PDW), which is in
general positively correlated with MPV, directly mea-
sures the variability in platelet size, and also represents a
parameter of platelet activity [12]. Several previous stud-
ies have assessed PDW values among patients with acute
coronary syndrome or coronary artery disease [13–15].
MPV may be increased in other cardiovascular conditions
such as pulmonary arterial hypertension [16], hypertrophic
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cardiomyopathy [17], and decompensated heart failure
[18, 19], which may explain the increase in thrombo-
embolic events in these conditions [20], Until now, only a
few studies with small sample sizes have examined the re-
lationship between MPV and left ventricular systolic and
diastolic dysfunction, and left ventricular hypertrophy
[21–23]. To this end, in the current study, we analyzed
the relationship between platelet indices (MPV, PDW) and
left ventricular systolic and diastolic cardiac dysfunction




The current retrospective study was approved by the
Ethics Committee of Osaka Medical College. Between
January 2012 and March 2014, 1241 patients who were
admitted to the Cardiology Department and had pro-
vided written informed consent and for whom sufficient
information regarding the data analysis for the current
study including echocardiographic data was available
were enrolled in the current study. Left ventricular dia-
stolic dysfunction (LVDD) was assessed among the pa-
tients with both sinus rhythm and left ventricular ejection
fraction (LVEF) of ≥50 %. Of 1241 overall study popula-
tion, 821 patients were found to have both sinus rhythm
and LVEF of ≥50 %. Among these patients, however, echo-
cardiographic data that was necessary for the determin-
ation of the presence or absence of diastolic dysfunction
was not available in 237 patients due to the poor echocar-
diographic imaging. Therefore, data from subgroup of 584
patients were used for the analysis of the relationship be-
tween platelet indices and LVDD.
Laboratory analysis
C-reactive protein (CRP) and B-type natriuretic peptide
(BNP) were measured by routine laboratory methods. The
eGFR was calculated by the following Modification of Diet
in Renal Disease equation for Japanese subjects: eGFR
mL/min/1.73 m2) = 194 × (serum creatinine) −1.094 × (age)
−0.287 (×0.739, when female) [24]. eGFR of less than
60 mL/min/1.73 m2 was defined as chronic kidney dis-
ease in the current study. MPV and PDW were analyzed
within 2 h of venipuncture by automatic blood counter
(ADVIA 2120i Hematology System; Siemens, Inc.) used
for whole blood analysis, with an intra-assay coefficient of
variation <1.4 % and 5.9 %, respectively.
Echocardiography
Echocardiographic examinations were performed as de-
scribed previously [25]. Briefly, left ventricular (LV) vol-
umes were calculated using the modified Simpson
method in the apical 4-chamber view. For calculation of
the LV mass (LVM), we used the formula proposed by
Devereux et al. [26] with modification: 0.8 × 1.04 ×
[(LVDd + IVST + PWT)3 - LVDd3] + 0.6. LVM index
(LVMI) was calculated as the ratio of LVM to the body
surface area. Left ventricular hypertrophy (LVH) was de-
fined to be present when the LVMI was greater than
118 g/m2 (men) or 108 g/m2 (women) [27]. The LVEF
was calculated by modified Simpson’s method using the
apical 4-chamber view and left ventricular systolic dys-
function (LVSD) was defined to be present when LVEF
was less than 50 %.
LVDD was assessed as previously described [28].
Briefly, the deceleration time of the E wave (DcT) and
peak velocities of early filling (E) and atrial filling (A)
were measured, and the early peak diastolic mitral annu-
lus velocity (e’), which was the mean of that obtained at
the septal and lateral mitral annulus, was measured
using pulsed wave tissue Doppler. LVDD was diagnosed
when any the following criteria were met; (1) E/e’ ≥ 15,
(2) 15 > E/e’ ≥ 8 and BNP ≥ 200, (3) 15 > E/e’ ≥ 8, E/A <
0.5, and DcT ≥ 280 msec, (4) 15 > E/e’ ≥ 8, E/A < 0.5 and
presence of LVH.
Statistical analysis
Baseline characteristics were assessed with standard de-
scriptive statistics. Data were expressed as either mean ±
standard deviation or median and interquartile range. A
Pearson’s correlation test was used to assess the correl-
ation between two variables. For multivariate analysis,
multivariate linear regression and multivariate logistic
regression analyses were used. Data analysis was per-
formed by SPSS statistics version 22.0 (IBM, Armonk,




Among the 1241 patients enrolled, 910 were male (73 %)
and 1008 (81 %) had sinus rhythm (Table 1). Only 53
(4 %) patients were undergoing chronic hemodialysis.
Platelet count was significantly negatively associated
with MPV and PDW, and MPV showed a significant
positive correlation with PDW (Fig. 1). Echocardiog-
raphy showed that 263 (21 %) patients had LVSD and
448 (36 %) had LVH.
Relationship between antithrombotic drug usage and
platelet indices
About one third of the study patients were taking anti-
coagulant medication and more than half were taking
aspirin and/or other antiplatelet drugs. Some platelet in-
dices differed between the anti-thrombotic drug users
and the non-users (Fig. 2); patients taking aspirin or clo-
pidogrel had significantly lower MPV as compared with
non-users (Fig. 2b). In addition, patients taking warfarin
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had a lower platelet count and higher MPV as compared
with non-users (Fig. 2d, e), although these values did not
significantly differ according to the use and non-use of
non-warfarin novel oral anticoagulants (NOAC).
It was found that the MPV value in patients with atrial
fibrillation (8.59 ± 0.91 fL) was significantly higher than that
in patients with sinus rhythm (8.25 ± 0.87 fL, P < 0.001).
When the comparison was limited to patients with sinus
rhythm, the MPV values in patients with warfarin usage
and that in patients without warfarin usage did not differ
significantly (8.24 ± 0.87 fL versus 8.34 ± 0.87 fL, re-
spectively, P = 0.202). In addition, MPV did not differ
significantly between warfarin users and non-users among
patients with sinus rhythm who were taking at least one
anti-platelet medication (8.33 ± 0.86 fL [n = 92] versus
8.21 ± 0.87 fL [n = 669], P = 0.203) or among patients
with sinus rhythm who were not taking any anti-platelet
medication (8.35 ± 0.91 fL [n = 53] versus 8.35 ± 0.87 fL
[n = 194], P = 0.959).
Relationship between platelet indices and left ventricular
systolic function and hypertrophy
When the data were assessed in tertiles, the prevalence of
LVSD seemed to increase according to the MPV (Fig. 3a)
or PDW (Fig. 3b) tertile, but not the platelet count tertile.
This tendency seemed to be less apparent for the preva-
lence of LVH (Fig. 3c, d). In univariate linear regression
analysis, platelet count, MPV, and PDW were each signifi-
cantly associated with both LVEF and LVMI (Table 2).
When stepwise multivariate analysis was performed by en-
tering all of the variables that used in univariate analysis,
MPV and PDW, but not platelet count, were found to
have a significant association with LVEF and LVMI.
Multivariate logistic regression analysis of the
relationship with left ventricular systolic dysfunction and
hypertrophy
Next, we performed multivariate logistic regression ana-
lyses using LVSD or LVH as a dependent variable (Tables 3
and 4). In this analysis, use of antiplatelet drugs and use of
warfarin were entered as independent variables. Warfarin
use was found to be, respectively, significantly and border-
line significantly positively associated with LVSD and
LVH. In model 1, where platelet indices were entered on a
per 1 standard deviation (SD) basis, PDW was, respect-
ively, significantly and borderline significantly associated
with LVSD and LVH. In this model, the association be-
tween MPV and LVH was not significant; however, in an
analysis adjusted for sex, age, anti-platelet drug use, and
warfarin use, MPV was significantly associated with LVSD
with an odds ratio of 1.26 (95 % CI 1.12–1.42, per 1 SD,
P < 0.001).
In model 2, where platelet indices were entered as tertile
basis, the highest tertile of MPV and PDW was associated
Table 1 Clinical characteristics of the study patients
Variables Women (n = 331) Men (n = 910)
Age, years 71.1 ± 10.9 68.3 ± 10.8
Body mass index, kg/m2 22.9 ± 4.1 23.7 ± 3.5
Chronic hemodialysis, n (%) 8 (2.4) 45 (4.9)
Ever smoker 55 (16.6) 721 (79.2)
Cardiac rhythm
Sinus rhythm, n (%) 258 (77.9) 750 (82.4)
Atrial fibrillation, n (%) 45 (13.6) 107 (11.8)
Pacemaker, n (%) 17 (5.1) 38 (4.2)
Others, n (%) 11 (3.3) 15 (1.6)
Cardiovascular disease
Ischemic heart disease, n (%) 173 (52.3) 681 (74.8)
Arrhythmic disease, n (%) 35 (10.6) 70 (7.7)
Cardiomyopathy, n (%) 113 (34.1) 217 (23.8)
Peripheral artery disease, n (%) 15 (4.5) 82 (9.0)
Valvular heart disease, n (%) 34 (10.3) 71 (7.8)
Medication
ACE inhibitors/ARB, n (%) 150 (45.3) 524 (57.6)
Beta blockers, n (%) 123 (37.2) 372 (40.9)
Calcium channel blockers, n (%) 162 (48.9) 389 (42.7)
Loop diuretics, n (%) 102 (30.8) 202 (22.2)
Thiazide diuretics, n (%) 25 (7.6) 38 (4.2)
Aldosterone antagonist, n (%) 35 (10.6) 79 (8.7)
Aspirin, n (%) 166 (50.2) 658 (72.3)
Clopidogrel, n (%) 88 (26.6) 393 (43.2)
Any antiplatelet drug, n (%) 176 (53.2) 689 (75.7)
Warfarin, n (%) 78 (23.6) 202 (22.2)
NOAC, n (%) 40 (12.1) 79 (8.7)
Any anticoagulants, n (%) 118 (35.6) 281 (30.9)
Laboratory data
White blood cell count, x103/μL 5.67 (4.60–6.86) 6.07 (4.98–7.27)
Hemoglobin, g/dL 12.4 (11.2–13.5) 13.6 (12.3–14.8)
Platelet count, x103/μL 212 (172–259) 201 (171–239)
Mean platelet volume, fL 8.1 (7.7–8.7) 8.2 (7.7–8.8)
Platelet distribution width, % 52.0 (47.3–56.2) 53.1 (48.3–58.0)
Serum creatinine, mg/dL 0.72 (0.62–0.93) 0.92 (0.80–1.13)
eGFR, mL/min/1.73 m2 60.4 (45.9–71.8) 47 (37.3–55.9)
Echocardiographic data
LV diastolic dimension, cm 4.6 (4.2–5.1) 4.9 (4.6–5.5)
LV systolic dimension, cm 2.9 (2.5–3.5) 3.3 (2.9–3.9)
LV ejection fraction, % 61 (54–68) 59 (51.0–65)
LV mass index, g/m2 99 (83–123) 106 (89.9–128)
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers;
NOAC, non-warfarin novel oral anticoagulants. For the data of serum creatinine
and eGFR, patients on chronic hemodialysis (n = 53) were excluded from
the analysis
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with LVSD with an odds ratio of 1.53 and 2.03, respectively,
compared with the respective lowest tertile (Table 3).
Relationship between platelet indices and left ventricular
diastolic dysfunction
Next, the relationship between platelet indices and LVDD
was investigated. Among 584 patients for whom presence
or absence of diastolic dysfunction was assessed, 71 patients
(12.2 %) were found to have LVDD. In model 1 where
platelet indices were entered on a per 1 SD basis, platelet
count and PDW, respectively, were found to be significantly
negatively and positively associated with LVDD (Table 5).
In this model, the association between MPV and LVDD
was not significant; however, in an analysis adjusted for sex,
age, anti-platelet drug use, and warfarin use, MPV was sig-
nificantly associated with LVDD with an odds ratio of 1.34
(95 % CI, 1.02–1.76, per 1 SD, P = 0.036). In model 2, where
platelet indices were entered on a tertile basis, the highest
tertile of PDW was associated with LVDD with an odds ra-
tio of 3.34 compared with the lowest tertile (Table 5).
Fig. 1 Correlation between platelet indices. a Correlation between platelet count and mean platelet volume (MPV). b Correlation between platelet count
and platelet distribution width (PDW). c Correlation between MPV and PDW
Fig. 2 Platelet indices according to antiplatelet or anticoagulative medication. Shown are platelet count (a), platelet volume (MPV) (b), and platelet
distribution width (PDW) (c) according to antiplatelet drug use, and platelet count (d), MPV (e), and PDW (f) according to anticoagulant medication use
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Discussion
In the current study, we analyzed platelet indices and car-
diac hypertrophy and left ventricular systolic and diastolic
function among cardiac patients. In a univariate analysis,
platelet count, MPV, and PDW were each correlated with
LVEF and LVMI; however, stepwise multivariate regres-
sion analysis showed that MPV and PDW, but not platelet
count, were independently associated with LVEF and
LVMI. By multivariate logistic regression analysis, the
highest tertile of MPV and PDW was associated with left
ventricular systolic dysfunction (LVEF < 50 %) with an
odds ratio of 1.53 and 2.03, respectively, as compared with
the respective lowest tertile (Table 3). Platelet count and
PDW were found to be independently associated with
LVH and with LVSD. MPV was associated with both LVH
and LVSD after adjusting for sex, age, anti-platelet drug
usage, and warfarin usage; however, after further adjust-
ment for covariates including platelet count and PDW,
these associations lost statistical significance, which was
explained, at least in part, by the inter-relationship among
platelet count, MPV, and PDW (Fig. 1).
Some studies previously showed the relationship be-
tween MPV and cardiac function/hypertrophy [19, 21–23].
In the current study, more than 1200 patients were studied
for the association between platelet indices and cardiac sys-
tolic dysfunction/hypertrophy, and more than 580 patients
were studied for the association between platelet indices
and cardiac diastolic dysfunction. We also carefully assessed
whether the antithrombotic medication use affected the ob-
served relation between platelet indices and cardiac parame-
ters. In addition, there have been no studies examining the
relationship between platelet indices and heart failure in Jap-
anese population.
Among the current study patients, approximately one-
third and more than half, respectively, were taking anti-
coagulant medication and antiplatelet drugs. MPV values
were lower among patients who were taking either aspirin
or clopidogrel as compared with those who were not
(Fig. 2b). Some studies have demonstrated that aspirin
[29, 30] or dual antiplatelet therapy [31] may not signifi-
cantly affect MPV, and one study showed a paradoxical in-
crease in MPV after antiplatelet therapy was started [32],
which might be related to a lack of patients response to clo-
pidogrel [33]. The reason why antiplatelet drugs reduced
MPV in the current study is unclear. Whether lower MPV
values predict cardiovascular risk or restenosis after percu-
taneous coronary intervention among patients taking anti-
platelet drugs [34] awaits future investigation.
Warfarin, but not NOAC, usage was found to be associ-
ated with the increased MPV value (Fig. 2e). Arik previously
reported that MPV was not significantly altered by warfarin
when it effectively prolonged international normalized ratio
Fig. 3 Prevalence of left ventricular systolic dysfunction (LVSD) and left ventricular hypertrophy (LVH) according to platelet indices. Shown is the
prevalence of LVSD (a, b) and LVH (c, d) according to platelet count and mean platelet volume (MPV) tertiles (a, c), and platelet count and platelet
distribution width (PDW) tertiles (b, d)
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among patients with non-valvular atrial fibrillation [35]. It
has been reported that MPV is higher in patients with atrial
fibrillation than in those with sinus rhythm [36, 37]. Be-
cause the association between warfarin use and MPV lost
statistical significance, irrespective of antiplatelet drug use,
when limited to the population with sinus rhythm in the
current study, the association observed between warfarin
and MPV may be attributed to the presence of atrial fibril-
lation. We also showed that NOAC did not affect platelet
factors. In several previous studies, a relationship between
MPV and left ventricular systolic function and hypertrophy
has been reported: for example, MPV has been found to
have a positive [22, 38] or no [39–41] association with LVH
and a negative association with LVEF [21, 42]. On the other
hand, most studies did not take PDW or antithrombotic
drug use into account.
LVDD may increase the risk of stroke [43, 44]. Although
previous studies demonstrated the platelet activation in
patients with heart failure [20, 45], a relationship between
platelet factors in patients with LVSD seems not to have
been specifically investigated. Our study found that plate-
let count and PDW, respectively, were negatively and
positively associated with LVDD among the subgroup of
patients who had sinus rhythm and preserved left ven-
tricular systolic function (Table 5). MPV was not inde-
pendently associated with LVDD after full adjustment
including PDW, which might be related to the fact that
PDW is a more specific marker of platelet activation [46].
Table 3 Multivariate logistic regression analysis of factors associated with LVSD
Independent variables Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
model 1 model 2
Sex (male = 1) 1.08 (0.74–1.58) 0.700 1.07 (0.73–1.56) 0.743
Age, per 1SD 0.83 (0.71–0.97) 0.018 0.83 (0.71–0.97) 0.017
Systolic blood pressure, per 1SD 0.87 (0.75–1.01) 0.059 0.87 (0.75–1.01) 0.062
Chronic kidney disease 1.56 (1.03–2.36) 0.036 1.60 (1.05–2.43) 0.027
Any antiplatelet drugs 1.00 (0.72–1.38) 0.997 0.98 (0.71–1.35) 0.888
Warfarin 2.18 (1.58–2.99) <0.001 2.18 (1.58–2.99) <0.001
White blood cell count, per 1SD 1.19 (1.03–1.37) 0.016 1.18 (1.03–1.36) 0.017
Hemoglobin, per 1SD 0.78 (0.67–0.90) 0.001 0.79 (0.68–0.91) 0.001
Platelet count, per 1SD 0.90 (0.76–1.06) 0.206
MPV, per 1SD 1.15 (0.98–1.35) 0.096
PDW, per 1SD 1.25 (1.06–1.46) 0.007
Middle platelet tertile 0.80 (0.56–1.14) 0.218
Highest platelet tertile 0.83 (0.56–1.23) 0.346
Middle MPV tertile 1.18 (0.80–1.73) 0.412
Highest MPV tertile 1.53 (1.04–2.27) 0.033
Middle PDW tertile 1.80 (1.22–2.64) 0.003
Highest PDW tertile 2.03 (1.37–3.02) <0.001
In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was
calculated using the corresponding lowest tertile
Table 2 Linear regression analysis of factors associated with
LVEF and LVMI
Univariate Multivariate (stepwise)
Std β P value Std β P value
Dependent variable: LVEF
Sex (male = 1) −0.10 <0.001 -
Age 0.07 0.011 0.14 <0.001
Systolic blood pressure 0.07 0.009 0.06 0.021
Chronic kidney disease −0.12 <0.001 −0.12 <0.001
White blood cell count −0.09 0.001 −0.06 0.034
Hemoglobin 0.06 0.047 0.08 0.007
Platelet 0.08 0.004 -
MPV −0.19 <0.001 −0.12 <0.001
PDW −0.18 <0.001 −0.13 <0.001
Dependent variable: LVMI
Sex (male = 1) 0.05 0.078 -
Age 0.09 0.002 -
Systolic blood pressure 0.09 0.002 0.09 0.001
Chronic kidney disease 0.15 <0.001 0.12 <0.001
White blood cell count 0.07 0.014 -
Hemoglobin −0.17 <0.001 −0.15 <0.001
Platelet count −0.09 0.001 -
MPV 0.15 <0.001 0.08 0.015
PDW 0.10 <0.001 0.07 0.016
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Table 5 Multivariate logistic regression analysis of factors associated with LVDD
Independent variables Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
model 1 model 2
Sex (male = 1) 0.42 (0.21–0.84) 0.014 0.37 (0.18–0.75) 0.006
Age, per 1SD 1.34 (0.95–1.89) 0.095 1.30 (0.92–1.83) 0.139
Systolic blood pressure, per 1SD 1.17 (0.89–1.56) 0.263 1.20 (0.91–1.60) 0.200
Chronic kidney disease 2.43 (1.12–5.30) 0.025 2.78 (1.24–6.24) 0.013
Any antiplatelet drugs 0.59 (0.30–1.15) 0.123 0.65 (0.33–1.29) 0.220
Warfarin 1.11 (0.47–2.61) 0.810 1.11 (0.47–2.62) 0.811
White blood cell count, per 1SD 1.54 (1.14–2.07) 0.005 1.52 (1.13–2.03) 0.005
Hemoglobin, per 1SD 0.50 (0.37–0.66) <0.001 0.51 (0.38–0.67) <0.001
Platelet count, per 1SD 0.62 (0.46–0.86) 0.003
MPV, per 1SD 0.92 (0.66–1.29) 0.641
PDW, per 1SD 1.41 (1.03–1.92) 0.031
Middle platelet tertile 0.42 (0.21–0.82) 0.011
Highest platelet tertile 0.32 (0.15–0.67) 0.003
Middle MPV tertile 1.00 (0.49–2.04) 0.991
Highest MPV tertile 0.88 (0.42–1.86) 0.738
Middle PDW tertile 1.91 (0.90–4.05) 0.092
Highest PDW tertile 3.34 (1.54–7.25) 0.002
In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was
calculated using the corresponding lowest tertile
Table 4 Multivariate logistic regression analysis of factors associated with LVH
Independent variables Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
model 1 model 2
Sex (male = 1) 0.87 (0.63–1.19) 0.386 0.86 (0.62–1.18) 0.356
Age, per 1SD 0.93 (0.81–1.06) 0.264 0.93 (0.81–1.06) 0.276
Systolic blood pressure, per 1SD 1.22 (1.08–1.37) 0.002 1.22 (1.08–1.38) 0.001
Chronic kidney disease 1.69 (1.20–2.36) 0.002 1.75 (1.25–2.46) 0.001
Any antiplatelet drugs 0.80 (0.61–1.05) 0.103 0.79 (0.60–1.04) 0.092
Warfarin 1.30 (0.97–1.74) 0.075 1.30 (0.97–1.74) 0.074
White blood cell count, per 1SD 1.12 (0.99–1.27) 0.074 1.11 (0.98–1.26) 0.101
Hemoglobin, per 1SD 0.72 (0.63–0.82) <0.001 0.72 (0.63–0.82) <0.001
Platelet count, per 1SD 0.93 (0.81–1.07) 0.303
MPV, per 1SD 1.10 (0.96–1.27) 0.171
PDW, per 1SD 1.12 (0.98–1.29) 0.095
Middle platelet tertile 0.80 (0.59–1.09) 0.160
Highest platelet tertile 0.94 (0.67–1.31) 0.697
Middle MPV tertile 1.15 (0.84–1.56) 0.388
Highest MPV tertile 1.28 (0.92–1.77) 0.139
Middle PDW tertile 1.39 (1.02–1.88) 0.035
Highest PDW tertile 1.56 (1.13–2.15) 0.007
In model 2, platelet indices used in model 1 were used replaced by tertile of these variables, and the odds ratio of the middle and the highest tertile was
calculated using the corresponding lowest tertile
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Notably, however, MPV was associated with LVDD with
an odds ratio of 1.34 (95 % CI 1.02–1.76) in a model ad-
justed for sex, age, and use of anti-platelet drugs and war-
farin. Whether PDW and MPV are useful parameters for
discriminating patients with LVDD and those at higher
risk for future thromboembolic risk and target organ dam-
age [38] needs to be investigated in future studies.
There are several limitations to the current study. First,
we did not directly assess the platelet aggregation induced
by ADP or other agonists. Second, because of the cross-
sectional nature of the study, we did not have data regard-
ing future thromboembolic risk among patients with high
MPV or PDW value. Third, whether MPV and PDW are
useful predictors of future thromboembolic risk and targets
for pharmacological intervention should be investigated in
future prospective studies. Fourth, as we did not directly
measure the platelet function, some conclusions may be
based on the speculative discussion. On the other hand, as
MPV and PDW are easily acquired parameters, we may
verify whether measurement of these parameters is of use
for prediction of cardiovascular events in future studies.
Conclusion
In conclusion, we herein demonstrated that usage of anti-
platelet drug and warfarin was related to MPV, and that
the platelet indices MPV and PDW, but not platelet count,
were independently associated with left ventricular systolic
function and mass index. Among patients with preserved
systolic function and sinus rhythm, the highest PDW tertile
was associated with LVDD with an odds ratio of 1.56 (95 %
CI, 1.13–2.15) when compared with the lowest PDW ter-
tile after multivariate adjustment. Whether these platelet
indices represent useful markers for discriminating those
at higher risk for thromboembolic disease and organ dam-
age among cardiac patients awaits further investigation.
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